March 24, 2020

Blue Light Cystoscopy System Approved for Marketing in China; “Blue Light Era” for Precision Treatment of Bladder Cancer Begins

Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs

Cevira® Endorsed with Level 1A Evidence in Expert Consensus, Establishing a New Benchmark for Non-Invasive Treatment of Cervical Precancerous Lesions

Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs

Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs

Asieris Receives Approval in Australia for Phase I Study of APL-2401 in Patients with FGFR2/3-Driven Advanced Solid Tumors

Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs

Asieris Pharmaceuticals Appoints Dr. Ningshu Liu as Chief Scientific Officer